Theremia is a precision medicine company specialized in CNS drug development. We combine proprietary biomedical knowledge graphs, causal AI, pharmacological modeling and patient-level data to turn complex biological and clinical information into actionable development decisions. We help biotech and pharma companies select the right indications, identify biomarkers and responder subgroups, optimize clinical trial design, generate real-world evidence, and improve treatment strategies. Our goal is to reduce clinical risk, accelerate decision-making and increase the probability of therapeutic success.